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trans-Platinum(II) complex of 3-aminoﬂavone –
synthesis, X-ray crystal structure and biological
activities in vitro†
Małgorzata Fabijańska,a Kazimierz Studzian,b Leszek Szmigiero,b
Agnieszka J. Rybarczyk-Pirek,c Arno Pﬁtzner,d Barbara Cebula-Obrzut,e
Piotr Smolewski,e Elżbieta Zynera and Justyn Ochocki*a
This paper describes the synthesis of trans-bis-(3-aminoﬂavone)dichloridoplatinum(II) (trans-Pt(3-af )2Cl2;
TCAP) for use as a potential anticancer compound, and the evaluation of its structure by elemental and
spectral analyses, and X-ray crystallography. The complex demonstrated a signiﬁcant cytotoxic eﬀect
against human and murine cancer cell lines, as well as weaker toxicity towards healthy cells (human peri-
pheral blood lymphocytes) in comparison with cisplatin. Various biochemical and morphological
methods conﬁrm that the proapoptotic activity of trans-Pt(3-af )2Cl2 is markedly higher than the reference
cisplatin. Our results suggest that trans-Pt(3-af)2Cl2 may have a diﬀerent antitumour speciﬁcity from that
of cisplatin.
Introduction
Metal compounds have been applied in cancer therapy since
1965, when Rosenberg discovered the cytotoxic activity of cis-
Pt(NH3)2Cl2 (cisplatin).
1,2 Despite being used for over 30 years
since their successful introduction in the clinic, major
problems concerned with the side-eﬀects and intrinsic or
acquired resistance still remain.3–5 The mechanisms under-
lying resistance to cisplatin may be connected with reduced
intracellular accumulation due to reduced drug uptake
enhanced eﬄux, conjugation with intracellular thiols (metallo-
thionein, glutathione), enhanced repair of platinum DNA
adducts or changes in molecular pathways involved in regu-
lation of cell survival/cell death.6,7 Based on the limitations in
the use of the platinum drugs, novel anticancer metal com-
pounds have been designed with the aim of reducing side-
eﬀects or synthesizing drugs with less propensity to induce
drug resistance.8 Early structure–activity relationship studies
suggest that the leaving groups, generally chloride, and two
ammine ligands in platinum complexes must be in a cis-con-
figuration and that the corresponding trans-compounds are
inactive. Nevertheless, since the 1990s, many trans-platinum
compounds have found use as potential drugs. Several scienti-
fic groups have reported trans-Pt compounds with in vitro
growth inhibitory and in vivo antitumor properties.9,10 More
importantly, some of these complexes have been found to
retain considerable eﬃcacy against tumor cells resistant to
cisplatin.11–15 Over the recent years, alternative approaches
were also focused upon metal complexes with ligands which
are important in medicinal and biological systems. Derivatives
of flavonoids known to possess diverse biological and pharmaco-
logical properties are particularly interesting ligand candi-
dates, in that they are cytotoxic to cancer cells but have no or
insignificant activity in normal cells. In addition, their antioxi-
dant, anti-inflammatory, antimicrobial and antiviral activities
have aroused great interest as candidates for the synthesis of
flavonoid synthetic derivatives.16,17 After all aminoflavone
[NSC686288; AFP464, NSC710464] is a new antitumour agent,
that is currently undergoing phase II clinical trials. This com-
pound demonstrated antiproliferative eﬀects in MCF-7 human
breast cancer cells mediated by the aryl hydrocarbon receptor.
Furthermore, the compound exhibits antitumor activity in vitro
and in vivo against neoplastic cells of the renal origin.18
The potential synergistic eﬀect between flavonoids and
metal ions as well as trans-geometry in platinum anti-tumour
complexes prompted us to synthesize trans-Pt(3-af )2Cl2 (3-af –
3-aminoflavone), denoted as TCAP. Furthermore, we were
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encouraged by the promising anticancer properties of its geo-
metric isomer (cis-Pt(3-af )2Cl2). This compound displays
in vivo and in vitro cytotoxic, genotoxic and proapoptotic
eﬀects towards cancer cells, as well as weaker toxicity than cis-
platin in normal lymphocytes.19–24 The present study describes
the synthesis, structural characterization and in vitro cytotoxic
and proapoptotic activity of trans-Pt(3-af)2Cl2 against cancer
cells and normal human peripheral blood lymphocytes; cispla-
tin was used as a reference compound.
Results and discussion
General observations
The novel platinum compound was synthesized according to
Scheme 1 and subsequently characterized by elemental ana-
lysis, ESI-MS, IR and NMR spectroscopy; X-ray analysis of the
structure was also performed. The anticancer activity was
studied using various cancer cell lines and normal human
lymphocytes.
Crystal structure description
The main aim of the X-ray crystallographic studies was to
determine the molecular structure and coordination geometry
of trans-Pt(3-af )2Cl2. Particular emphasis was placed on identi-
fying potential binding sites of the 3-aminoflavone ligand,
nitrogen or oxygen atom, especially with respect to other pre-
viously-determined structures.25–27 Fig. 1 shows a displace-
ment ellipsoid plot of the molecule with an atom-labeling
scheme. The structure of the complex is composed of one
platinum cation, two 3-aminoflavone ligands in their neutral
form and two chloride anions.
In the crystal lattice, two nitrogen N(3) atoms of the
3-aminoflavone ligand and two chloride Cl(1) anions are
bound to a central platinum(1) atom lying on crystallographic
inversion in a slightly distorted planar square. This distortion
of square planar coordination results from diﬀerences in the
metal–ligand bond lengths. The bond distances around the
Pt(1) atom and its neighboring N(3) and Cl(1) atoms, as well as
respective valence angles are presented in Table 1. The length
of the Pt–N bond, 2.064(5) Å, is significantly longer than that
for the other complexes with the same ligand, which are about
1.986(3) Å for the Cu–N bond25,26 and 1.910(4) for the Ru–N
bond.27 The plane, defined by Pt(1), N(3), Cl(1), N(3)#, Cl(1)#
atoms (symmetry code #: −x, −y + 1, −z + 1), is planar within
experimental errors. The atoms of the same element occupy
trans positions of the basal coordination plane.
The complex molecule consists of several planar fragments.
Plane A is the central plane of the molecule described above,
formed as a result of coordination, involving a central Pt(1)
atom, two N(3) and two Cl(1) atoms. With regard to the 3-amino-
flavone moiety, two other planes may be defined: plane B
comprising condensed phenyl-pyrane rings (O(1), C(2), C(3),
C(4), C(5), C(6), C(7), C(8), C(9), C(10) atoms) and plane C of
the phenyl substituent (C(11), C(12), C(13), C(14), C(15), C(16)
atoms). The conformation of the benzopyrane moiety may be
regarded as essentially planar, with a maximum deviation
from the adequate least square plane B of 0.023(6) Å, observed
for the C(4) atom. The coordination (A) and benzopyrane (B)
planes are close to perpendicularity, with a dihedral angle
equal to 78.1(2)°. The phenyl substituent (plane C) forms di-
hedral angles of 50.5(2)° and 52.8(2)° with planes A and B,
respectively. The corresponding planes related by the inversion
center are situated parallel to each other. Moreover C(5), C(6),
C(7), C(8), C(9), C(10) phenyl rings of neighboring molecules
Table 1 Summary of the IC50 values of trans-Pt(3-af)2Cl2 and cisplatin
on tumour cells and lymphocytes
IC50 (µM)
trans-Pt(3-af)2Cl2 Cisplatin
L1210 6.6 ± 0.7 1.00 ± 0.14
L1210R 4.6 ± 0.5 (0.7)a 2.4 ± 0.11 (2.4)a
HL-60 8.1 ± 1 2.1 ± 0.2
HeLa 8.3 ± 0.7 2.1 ± 0.3
EJ 16.3 ± 0.3 1.6 ± 0.5
EJcisR 14.2 ± 1.5 (0.87)a 11.7 ± 1.5 (7.3)a
Lymphocytes 9.3 ± 2.1 0.8 ± 0.2
a Resistance factor, defined as IC50(resistant)/IC50(sensitive), is given in
parenthesis.
Fig. 1 A displacement ellipsoid plot of the complex molecule with a
non-H atom labeling scheme. Unlabelled atoms are related by an inver-
sion centre. Atomic displacement ellipsoids are drawn at a 50%
probability level. Selected bond lengths [Å] and angles [°]: Pt(1)–N(3)
2.064(5), Pt(1)–Cl(1) 2.298(1), N(3)–Pt(1)–Cl(1) 92.7(1), C(3)–N(3)
1.443(7), C(2)–C(3) 1.355(8), C(3)–C(4) 1.451(8).
Scheme 1 Synthesis of trans-Pt(3-af)2Cl2 and Pt(3-af)Cl2 (see
Experimental).
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are stacked in the crystal structure with interplanar distances
3.589(3) Å and 3.551(3) Å. This stacking is accompanied by
respective ring slippage equal to 1.481(4) Å and 1.546(4) Å.
With regard to the structure of the 3-aminoflavone ligand,
the diﬀerentiation of C–C bond lengths within the pyrane
system is typical,28–32 varying from 1.355(8) Å to 1.460(8) Å for
C(2)–C(3) and C(4)–C(10) bonds, respectively. Moreover, coordi-
nation to the Pt(1) cation increases the C(3)–N(3) bond length
by about 0.04 Å in comparison with a free ligand −1.396(2),26
while the C(4)–O(4) bond distance of 1.231(7) Å is in line with
a double bond.33
The crystal-packing arrangement is mainly directed by
hydrogen bonding interactions. Conventional hydrogen bonds
are formed between the nitrogen N(3) atom of an amine group
and the carbonyl O(4) atom (symmetry: −x + 1, −y + 1, −z + 1).
Geometrical parameters typical for such an interaction are
included in Table S1.† The intermolecular distance N(3)⋯O(4)
equal to 2.868(7) Å, and the angle N(3)–H(3A)⋯O(4) of 155.7°
are indicative of medium–strong hydrogen bonds. As a result
of this intermolecular hydrogen bond a centrosymmetric
R2
2(10) ring motif according to graph-set notation34 is closed.
However, taking into account that one complex molecule is
linked by four N–H⋯O interactions, in two as a proton donor
and in two as a proton acceptor, the hydrogen bonding
network becomes more complicated. The obtained scheme of
the N–H⋯O hydrogen bonding network is shown in Fig. 2.
Thus, N(3)–H(3A)⋯O(4) hydrogen bonds also connect mole-
cules related by translation along the a-axis of the unit cell,
forming a chain motif C(7). However, as only half the molecule
occupies an asymmetric unit, molecules linked into a chain
are also centrosymmetrically paired into the mentioned rings.
Finally, the intermolecular hydrogen bond pattern can be
described as an infinite chain of centrosymmetric rings,
running along the [100] direction with respective graph set
C(7)[R2
2(10)].
Another two hydrogen bonds, defined by a hydrogen⋯
$acceptor distance shorter than the sum of van der Waals
radii, are formed between C–H donors and a chloride anion
Cl(1) or oxygen atom O(4). Relatively long intermolecular
distances suggest that they may be classified as rather weak
interactions. Details of these hydrogen bonds are given in
Table S2.†
Cytotoxicity evaluation (MTT assay)
trans-Pt(3-af)2Cl2 revealed significant cytotoxicity towards all
tested cell lines with IC50 values in the 4.6–16.3 µM range
(Table 1). TCAP was found to be slightly less cytotoxic to the
tested cancer cell line than cisplatin. Furthermore, TCAP was
also less toxic for normal lymphocytes in comparison with cis-
platin, which is especially desirable for the prevention of
potential drug side-eﬀects. The concentrations causing 50%
inhibition of lymphocyte proliferation were 9.3 µM for TCAP
and 0.8 for cis-DDP.
For TCAP no significant diﬀerences were observed between
L1210 and EJ cells and their cisplatin-resistant sublines:
L1210R and EJcisR. Hence, TCAP has the ability to retain cyto-
toxic activity against cisplatin-resistant cell lines, which could
be explained as alternative mechanisms of action. Addition-
ally, TCAP demonstrated a slightly greater cytotoxic eﬀect on
cisplatin-resistant lines than sensitive sub-lines. This is an
interesting finding, as cisplatin was 2- and 7-times less active
toward L1210R and EJcisR cells, respectively. With respect to
incubation time, our findings reveal no diﬀerences in the cyto-
toxicity of TCAP towards cancer cells when applied for 72 h
and for shorter times of 24 h and 48 h (see Fig. S1†). Free
3-aminoflavone was not cytotoxic at concentration up to
100 µM.35 These results are very promising, as they indicate
that TCAP has beneficial features for potential anticancer
agents.
Apoptosis evaluation
Apoptotic pathways are important targets that should be con-
sidered in the design of potential anticancer agents. It is
especially advantageous if the new compound triggers the
death of cancer cells by apoptosis. Apoptosis is a tightly-regu-
lated process characterized by several morphological and
biochemical features, including changes in the kinetics of
phosphatidylserine exposure on the outer leaflet of the plasma
membrane, changes in mitochondrial membrane permeability
leading to the release of apoptotic proteins, and activation of
caspase and cleavage of nuclear DNA.
To better understand the nature of the promising cytotoxic
activity demonstrated by TCAP, its eﬀects at the cellular level,
particularly, the mechanism of cell death, were subjected to
further tests. Several diﬀerent methods were used to compare
the activities of trans-Pt(3-af)2Cl2 and cisplatin in inducing
apoptosis in model cancer cell lines.
Measurement of mitochondrial transmembrane potential
(ΔΨm)
One of the best-known aspects of mitochondrial involvement
in apoptosis is the onset of multiple parameters of mitochon-
drial dysfunction including membrane depolarization. Flow
cytometric analysis of transmembrane potential has been used
to determine whether the trans-Pt(3-af)2Cl2 compound might
directly target mitochondria in tumor cells to cause the
Fig. 2 The supramolecular chain of the ring motif of molecules linked
by N(3)–H(3A)⋯O(4) intermolecular hydrogen bonds in a crystallo-
graphic [100] direction. N–H⋯O hydrogen bonds are shown with
dashed lines. Geometric parameters: N(3)⋯O(4) 2.868(6) [Å] and N(3)–
H(3A)⋯O(4) 155.7 [°] and symmetry code i: −x + 1, −y + 1, −z + 1.
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collapse of mitochondrial membrane potential (ΔΨm) which is
linked to permeability by transition pore opening, leading to
apoptosis. MitoTracker Red was used as a probe of ΔΨm. The
drop of ΔΨm was detected by flow cytometry as a decrease in
red fluorescence of the dye in treated cells as compared to
untreated cells. Fig. 3 shows the eﬀects of TCAP and cisplatin
on mitochondrial transmembrane potential in L1210 cells.
The obtained results indicate that the complex induces a col-
lapse of the mitochondrial membrane potential, as assessed
by the dose- and time-dependent increase in the percentage of
cells with depolarized mitochondria. Indeed, at a concen-
tration of 15 µM TCAP, about 75% of the cells were found to
be aﬀected after 6 hours. Interestingly, cisplatin was found to
be ineﬀective under the same conditions, with no more than
15% of cells being detected as a collapse of ΔΨm positive,
which suggests that it has a diﬀerent target to TCAP.
Caspase-3 activity
The next set of tests was performed to determine whether a
drop in mitochondrial membrane potential occurring at early
stage of apoptosis precedes the caspase-3 activation. Caspase-3
activation was chosen as an indicator of apoptosis induction,
as diﬀerent upstream pathways leading to apoptosis depend
on it for final apoptotic execution.
Leukemia cells (L1210) were incubated with TCAP and cis-
platin for 2, 4 and 6 hours to estimate the time needed to
initiate the apoptosis process. The obtained results show that
up to 40% of the cells undergo apoptosis after 4 h incubation
with 10 µM TCAP, while this number increases to 60% at
15 µM TCAP. Furthermore, when incubation was prolonged to
6 h, 70% to 75% of the treated cells were aﬀected. Interest-
ingly, cisplatin was found to be ineﬀective under the same con-
ditions, with no more than 10% being detectable as a caspase-
3 positive at 10 µM and 15% 15 µM. The cells with active
caspase-3 were confirmed to have significant involvement in
the caspase-dependent apoptotic pathway. Furthermore, Fig. 3
and 4 indicate that the collapse of mitochondrial transmem-
brane potential (ΔΨm) induced by TCAP is strictly correlated
with the triggering of the intrinsic proapoptotic pathway with
the eﬀector caspase-3.
As the minimum time needed to induce apoptosis was
found to be 4 h, the next stage of the study was incubation of
the cells with tested compounds for 4 h and then postincuba-
tion in fresh medium for 20 hours to evaluate whether the
initiated apoptosis process will continue despite the lack of
drugs. The results are shown in Fig. 5 and 6. All three leukemia
cell lines treated with TCAP showed increasing degrees of
caspase-3 positivity in a dose-dependent manner, indicating
that the cells were undergoing apoptosis. It was observed that
Fig. 4 Flow cytometric analysis of active-caspase-3 cells. Percentage
of apoptotic cells in L1210 cell culture following trans-Pt(3-af)2Cl2
(TCAP) and cisplatin (cis-DDP) treatment after 2 h, 4 h and 6 h incu-
bation. Results shown are representative data of at least three individual
studies.
Fig. 5 Flow cytometric analysis of active-caspase-3 cells. Percentage
of apoptotic cells in L1210, L1210R and HL-60 cell culture following
trans-Pt(3-af)2Cl2 treatment after 4 h incubation and 20 h postincuba-
tion. Results shown are representative data of at least three individual
studies.
Fig. 3 Flow cytometric analysis of cells with low ΔΨm. Percentage of
apoptotic cells in L1210 cell culture following trans-Pt(3-af)2Cl2 (TCAP)
and cisplatin (cis-DDP) treatment after 2 h, 4 h and 6 h incubation.
Results shown are representative data of at least three individual studies.
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TCAP induced apoptosis as much as three times more eﬀec-
tively (L1210R) than cisplatin, with the population of the
apoptotic cells ranging between 80 and 90% at its highest
concentration.
Annexin-V staining
Exposure of phosphatidylserine (PS) on the external surface of
the cell membrane has been shown to occur in the early stages
of apoptotic cell death and can be detected using Annexin-V.
Leukemia cells (L1210, L1210R and HL-60) were treated with
TCAP and cisplatin for 4 hours, postincubated in fresh
medium for 20 hours at concentrations of 10 µM and 15 µM,
and then collected for Annexin-V-FITC/propidium iodide
staining.
The assays showed that the studied compound induced
apoptosis of the majority of cells. All the three leukemia cell
lines treated with TCAP showed increasing degrees of Annexin-V
positivity in a dose-dependent manner, indicating that the
cells were undergoing apoptosis. This assay confirmed that
the apoptosis process is continuous despite the removal of
the drug (Fig. 7 and 8).
Apoptotic DNA fragmentation
To check whether DNA degradation may be a result of the
apoptosis process, gel electrophoresis of DNA extracted from
the cells was assessed. After 4 h drug exposure and 20 h or
44 h post-drug incubation, gel electrophoresis was performed
with DNA extracted from the cells treated with the drug
(Fig. 9). Distinct DNA laddering was observed when cells were
treated with TCAP at concentrations equivalent to 2× IC50
(lines 3, 10) and 3× IC50 (lines 3, 11). DNA laddering was much
weaker, in fact it was barely visible when cells were treated
with cisplatin at equivalent doses of 2× IC50 and 3× IC50. When
postincubation was prolonged up to 40 h, both TCAP and cis-
platin demonstrated a clearly evident DNA laddering pattern:
lines 10, 11 and 12, 13, respectively. These results may suggest
that the detected DNA degradation caused by TCAP indicates
the presence of apoptosis. For both tested compounds, DNA
appeared as characteristic ladder-like fragments, which is the
biochemical hallmark of apoptosis. The results were compared
to the negative control (untreated cells) where no laddering
pattern or smear was seen.
Acridine orange and ethidium bromide staining (AO/EB)
Acridine orange and ethidium bromide staining was used to
compare proapoptotic potential of the tested trans-platinum(II)
compound with that of cisplatin towards both the sensitive
and the resistant lines of mouse leukemia cells. Fluorescent
dyes used in the assay bind DNA in the cells and enable apop-
totic, necrotic and normal cells to be distinguished. Morpho-
logical cellular changes that are characteristic hallmarks of
programmed cell death included abnormal shape and volume,
loss of cell membrane asymmetry, nuclear and chromatin
condensation, and blebbing of the plasma membranes (see
Fig. 6 Flow cytometric analysis of active-caspase-3 cells. Percentage
of apoptotic cells in L1210, L1210R and HL-60 cell culture following cis-
platin (cis-DDP) treatment after 4 h incubation and 20 h postincubation.
Results shown are representative data of at least three individual studies.
Fig. 8 Flow cytometric analysis of Annexin-V-positive cells. Percentage
of apoptotic cells in L1210, L1210R and HL-60 cell culture following cis-
platin (cis-DDP) treatment after 4 h incubation and 20 h postincubation.
Results shown are representative data of at least three individual studies.
Fig. 7 Flow cytometric analysis of Annexin-V-positive cells. Percentage
of apoptotic cells in L1210, L1210R and HL-60 cell culture following
trans-PtCl2(af )2 treatment after 4 h incubation and 20 h postincubation.
Results shown are representative data of at least three individual studies.
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Fig. S2†). The results after 4 h of incubation and 20 h postincu-
bation in fresh medium are shown in Fig. 10 and 11.
Our results reveal that trans-Pt(3-af )2Cl2 induce apoptosis
more eﬀectively than cisplatin. At 10 µM TCAP causes apopto-
sis induction in about 30% of the cells, while cisplatin was
found to cause apoptosis in about 20%. Furthermore 15 µM of
the TCAP compound is suﬃcient to induce apoptosis in the
majority of cells of both lines; a proapoptotic eﬀect is observa-
ble in about 90% of cells. This experiment shows that the pro-
apoptotic activity of compound 2 is 2- to 4-times higher than
that of cisplatin. Therefore, our findings indicate that TCAP
inhibits tumour cell proliferation and causes cytotoxicity via
programmed cell death.
Experimental
Chemicals
3-Hydroxyiminoflavanone, 3-aminoflavone, and the two Pt(II)
complexes were synthesized as described below. Other
reagents were purchased from Sigma-Aldrich, Alfa Aesar and
POCh (Poland).
Synthesis of 3-aminoflavone (3-af)
The synthesis followed the procedure described elsewhere.28
Synthesis and characterization of trans-Pt(3-af )2Cl2
Synthesis of trans-Pt(3-af )2Cl2. To the solution of 3-amino-
flavone (3-af ) (0.273 g, 1 mmol) in dry ethyl acetate (200 ml)
platinum chloride(II) (0.133 g, 0.5 mmol) was added. The
mixture was stirred under reflux for 6 h with protection from
light. The precipitate was filtered oﬀ, washed with dry ethyl
acetate and air dried. A yellow powder was obtained with a
yield of 0.223 g (61%) (Pt(3-af )Cl2). The filtrate was concen-
trated and left to evaporate slowly to allow the complex to
crystallize. The obtained yellow crystals, suitable for X-ray
measurement, were then filtered and dried: the yield was
0.066 g (18%); M.p. 247–252 °C (trans-Pt(3-af )2Cl2; TCAP). The
complex is soluble in DMSO, DMF; moderately soluble in
methanol, 2-propanol and acetonitrile; insoluble in water,
diethyl ether and acetone.
The structure of Pt(3-af)Cl2 was determined by elemental
analysis, IR and FAB-MS spectroscopy but further X-ray experi-
ment is still required.
The structure of trans-Pt(3-af)2Cl2 was determined by
elemental analysis, IR, 1H NMR, 13C NMR spectroscopy and
Fig. 10 Fluorescence microscopy analysis. Percentage of apoptotic
cells in L1210 and L1210R cell culture treated with trans-Pt(3-af)2Cl2 for
4 h and postincubated for 20 h evaluated by acridine orange/ethidium
bromide nuclear staining. Results shown are representative data of at
least three individual studies.
Fig. 11 Fluorescence microscopy analysis. Percentage of apoptotic
cells in L1210 and L1210R cell culture treated with cisplatin (cis-DDP) for
4 h and postincubated for 20 h evaluated by acridine orange/ethidium
bromide nuclear staining. Results shown are representative data of at
least three individual studies.
Fig. 9 Agarose gel electrophoresis of DNA from treated cells. L1210R
cells were exposed to drugs for 4 h and then postincubated in a drug-
free medium for the following 20 h (tracks 1–6) or 44 h (tracks 8–13).
DNA was isolated from the cells and run on a 1.8% agarose gel as
described in the Experimental section. Tracks: 1, control (untreated);
2, control + DMF; 3, TCAP (2× IC50); 4, TCAP (3× IC50); 5, cisplatin
(2× IC50); 6, cisplatin (3× IC50); 7, marker (DNA ladder 123 bp); 8, control
(untreated); 9, control + DMF; 10, TCAP (2× IC50);11, TCAP (3× IC50); 12,
cisplatin (2× IC50); 13, cisplatin (3× IC50).
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electrospray mass spectrometry. C30H22Cl2N2O4Pt (740.49 g mol
−1):
calculated. C 48.66; H 2.99; N 3.78; found: C 48.63; H 2.56;
N 3.63(%). Selected IR data (KBr, cm−1): 3265.4, 3119.1,
3072.9 (NH2), 1633.5 (CO), 1549.2 (CNH2), 489.0 (PtN).
1H
NMR DMF-d7 (δ, ppm): 6.40 (s, 2H, NH2), 7.58–7.61 (1H, m),
7.72–7.76 (3H, m), 7.88–7.92 (1H, m) 8.04 (1H, dd), 8.54–8.57
(2H, m) (Fig. S3†). 13C NMR, DMF-d7 (δ, ppm): 172.9, 156.11,
154.71; 134.85, 131.56, 131.32, 129.48, 129.06, 125.81, 125.72,
125.23, 121.45, 118.87 (Fig. S4†). ESI+-MS (methanol) m/z: 763
[Pt(3-af)2Cl2 + Na]
+, 669 [Pt(3-af)2]
+ 238 (3-af)+. Melting point
was determined with Böetius apparatus. Microanalyses of C, H
and N were performed with a Perkin Elmer 2400 analyzer. 1H
NMR and 13C NMR experiments were carried out on a Bruker
Avance III (500 MHz) spectrometer using DMF-d7 as a solvent.
IR spectra were carried out on an ATI Mattson Infinity Series
FTIR™ spectrometer using KBr pellets. Electrospray ioniza-
tion-mass spectra (ESI-MS) were obtained in positive ion mode
on a Varian 500-MS LC ion trap using methanol as the solvent.
X-ray structure determination and refinement
A representative crystal of a suitable size was selected and
mounted on a fiber loop and used for X-ray measurements.
X-ray data were collected at low temperature on a Stoe IPDS
diﬀractometer36 with a monochromated Mo Kα X-ray source.
Data reduction was performed with the Stoe IPDS software
which added Lorentz and polarization corrections. The crystal
structure was solved by direct methods using SHELXS-8637
and refined by the full-matrix least squares method using
SHELXL-9737 (both programs implemented in WinGX38).
Refinement was carried out on F2 by full-matrix least-squares
procedures with minimized function ∑w(Fo2 − Fc2)2. All non-
hydrogen atoms were refined with anisotropic displacement
parameters. Hydrogen atoms of the phenyl rings were intro-
duced in calculated positions with idealized geometry while
amine hydrogen atoms were located on a diﬀerence Fourier
map. In the last step of the refinement all the hydrogen atoms
were constrained to ride on their parent atoms using a rigid
body model with isotropic displacement parameters equal to
1.2Ueq of appropriate N or C atom. A summary of the crystallo-
graphic data is given in Table 1. The molecular geometry was
calculated by PARST39 and Platon.40 Selected bond distances
and angles are summarized in Table 2. Mercury version 2.441
was used to present the intermolecular interaction network.
The coordinates and displacement parameters of the atoms
are deposited with Cambridge Crystallographic Data Centre.
CCDC 811964 number contains the supplementary crystallo-
graphic data for this paper.
Cell cultures
The in vitro anticancer chemotherapeutic potential of the
platinum(II) complex was determined using murine (L1210,
L1210R) and human (HL-60, HeLa, EJ, EJcisR) cancer cell lines
and human lymphocytes. The cells were cultured in RPMI (Bio-
logical Industries) medium supplemented with 10% foetal
bovine serum (Biological Industries) and gentamycin (Biologi-
cal Industries, 50 µg ml−1) in an atmosphere of 5% CO2.
Cisplatin and TCAP for the assays were dissolved in DMF, with
the DMF concentration in the cell incubation medium being
0.2%.
Lymphocytes were isolated from peripheral blood of
healthy donors, purchased from the Regional Blood Bank of
Lodz, Poland with the approval of the Local Ethical Commit-
tee. Blood was collected in Monovette™ tubes with sodium
citrate and processed within 3 h. Centrifugation was carried
out in a density gradient using Histopaque-1077 (Sigma). Lym-
phocytes were cultured in RPMI 1640 medium supplemented
with 10% foetal bovine serum (Biological Industries), phyto-
hemagglutinin-M (Biological Industries) and gentamycin (Bio-
logical Industries) in an atmosphere of 5% CO2.
MTT assay
Each compound was tested for its cytotoxic activity in vitro
against the cells of six cancer cell lines: HL-60 (human promyelo-
cytic leukemia cell line), EJ (bladder cancer cell line), EJcisR
(bladder cancer cell line resistant to cisplatin), HeLa (cervical
cancer cell line), L1210 (mouse leukemia cell line) and L1210R
(mouse leukemia cell line resistant to cisplatin). Human lym-
phocytes were used to assess the toxicity of the tested com-
pounds towards normal cells. The cytotoxicity of trans-Pt-
(3-af)2Cl2 was evaluated using the MTT assay, a colorimetric
method based on the measurement of energetic cell meta-
bolism (succinate dehydrogenase activity). The results of cyto-
toxic activity in vitro are expressed as IC50 values, i.e. the
concentration of compound in µM needed to inhibit 50% of
Table 2 Crystal data and structure reﬁnement details
Crystal data
Formula C30H22Cl2N2O4Pt
Formula weight 740.49
Crystal system, space group Triclinic, P1ˉ
Unit cell dimensions a = 6.9226(4) Å
b = 9.2809(8) Å
c = 11.0038(9) Å
α = 85.511(7)°
β = 87.997(6)°
γ = 77.091(7)°
V 686.88(9) Å3
Z, dx 1, 1.790 g cm
−3
F(000) 360
Crystal size 0.10 × 0.08 × 0.05 mm
Data collection
Temperature 123 K
Radiation type, wavelength Cu Kα, 1.54178 Å
θ Range for data collection 4.03 to 62.45°
Limiting indices −7 ≤ h ≤ 7
−10 ≤ k ≤ 10
0 ≤ l ≤ 12
Reflections collected/unique 6975/2143 [R(int) = 0.0461]
Completeness 98.2%
Refinement
Refinement method Full-matrix least-squares on F2
Data/restraints/parameters 2143/0/178
Goodness-of-fit on F2 1.144
Final R indices [I > 2σ(I)] R1 = 0.0309, wR2 = 0.0742
R indices (all data) R1 = 0.0347, wR2 = 0.0811
Largest diﬀ. peak and hole 1.315 and −1.783 e Å−3
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tumor cell growth as compared to control untreated cells. Cis-
platin was used as a reference compound.
In this assay, yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) is reduced to purple formazan
in the mitochondria of living cells and the amount of pro-
duced formazan is measured colorimetrically. The cells were
seeded in triplicates on 24-well plates (1.5 × 103 cells per 1 ml
of medium for L1210 and L1210R; 2 × 104 per ml for EJ; 5 ×
104 per ml for EJ-CPR; 1 × 104 per ml for HeLa; 1 × 104 per ml
for HL-60) and left for 24 h. The cells were then treated with
the tested compounds dissolved in DMF (N,N-dimethylform-
amide; concentration of DMF in cell cultures was 0.2%). After
a 72 h incubation at 37 °C, 0.1 ml of MTT solution (5 mg ml−1
in PBS) was added to each well and the plates were incubated
for a further 2–3 h (4 h for lymphocytes). After removing the
medium, the purple formazan precipitate was dissolved in
DMSO and the absorbance was measured at 540 nm using an
Ultrospec III UV/VIS spectrophotometer. Cytotoxic activity was
expressed as percentage of the cellular growth inhibition in
culture treated with complex compounds assuming the
control, treated with DMF as 100%. The results are presented
as means of at least three independent experiments.
Acridine orange and ethidium bromide staining (AO/EB)
The murine leukemia cells (L1210, L1210R) were seeded on
the tested tubes (5 × 104 cells per 1 ml of medium). The next
day the tested compounds were added and the tubes were
incubated at 37 °C for 4 h, before being incubated in fresh
medium for another 20 h. After the times indicated below, the
cells were collected and centrifuged (10 min/1500 rpm/23 °C).
The cell pellets were suspended in 0.1 ml of medium
with 0.025 ml of the staining mixture (acridine orange and
ethidium bromide, 0.1 mg ml−1 in PBS). After stirring,
the cells were placed on slides and observed under a fluore-
scence microscope ( = 480–550 nm). At least 200 cells from
each slide were counted, and the percentage of apoptotic cells
was calculated on the basis of cellular morphological features.
The results are shown as the mean of the three independent
experiments.
Genomic DNA electrophoresis (DNA ladder)
This assay was used to detect DNA degradation resulting from
apoptosis. The cells were treated with the tested compounds
for 4 h at 37 °C in the growth medium. Following this, they
were lysed on polycarbonate filters with 5 ml of 2% sodium
dodecyl sulphate dissolved in 0.01 M EDTA (pH = 10).
L1210R cells were treated with TCAP and cisplatin, collected
by centrifugation and fixed in 70% ethanol. The cells were cen-
trifuged at 1500 rpm for 5 min to remove the ethanol. The cell
pellets were resuspended in 0.5 ml of pH buﬀer (45 mM tri-
sphosphate-borate, 1 mM EDTA, 0.25% Nonidet) and digested
by DNase-free RNase A (Sigma, USA, 1 mg mL−1) for 30 min at
37 °C and later by proteinase K (1 mg ml−1, 30 min at 37 °C).
After digestion, 0.1 ml of loading buﬀer (0.25% bromophenol
blue, 30% glycerol) was added and 70 µL of DNA solutions
were applied on the 1.8% agarose gel containing 0.5 µg ml−1
of ethidium bromide. Electrophoresis was performed at 1.2 V
cm−1 for 17 h. The DNA in gels was visualized under UV light
and photographed using Ilford FP4 negative film.
Activation of caspase-3 measurement
The main eﬀectors of apoptosis are proteases belonging to the
caspase family. Caspases represent key mediators in the
initiation and execution of apoptosis. Active caspase-3 was
detected using FITC conjugated rabbit antibody against active
caspase-3 (BD Pharmingen).
Briefly, cells were seeded into test tubes and treated with
appropriate concentrations of TCAP and cisplatin. After
incubation, the cells were recovered and washed twice with
phosphate-buﬀered saline (PBS), before being fixed and per-
meabilized using Cytofix/Cytoperm™ (BD Pharmingen) solu-
tion (20 min, on ice), washed twice and resuspended in the
Perm/Wash™ buﬀer (BD Pharmingen, San Diego, CA, USA).
The antibody was added to 10 µl per 100 µl of cell suspension
(30 min incubation, RT). The fluorescence was measured
directly after staining and washing with Perm/Wash™ buﬀer
by flow cytometry (FL1, green fluorescence filter).
Annexin-V/PI propidium iodide assay
The apoptotic cells were identified by flow cytometry using the
Annexin-V/FITC (BD Pharmingen™) assay according to the
manufacturer’s instructions.
For detection of apoptosis and necrosis, FITC-labeled
Annexin-V combined with PI was used to mark the presence of
phosphatidylserine (PS), which is displayed during apoptosis
at the cell surface. PI only stains the nuclei of damaged cells
with permeable plasma membranes.
Briefly, the cells were incubated with TCAP and cisplatin for
4 h and then incubated in fresh medium for 20 h. After incu-
bation the cells were washed twice with cold PBS and then
resuspended in 100 µL of binding buﬀer, containing 2 µL of
FITC conjugated Annexin-V and 10 µg ml−1 of PI (Becton-
Dickinson, San Jose, CA, USA). Then, the preparations were
incubated at room temperature, protected from light, for
15 min. Fluorescence was measured immediately after staining
by flow cytometry using FL1 (green, Annexin-V) and FL3 (red,
PI) standard fluorescent filters.
Collapse of mitochondrial transmembrane potential (ΔΨm)
assessment
The dissipation (collapse) of mitochondrial transmembrane
potential (ΔΨm) occurs early during apoptosis and is often
considered as a marker of apoptosis activated by the mito-
chondrial pathway. MitoTracker Red dye was used as a probe
for ΔΨm, which accumulates in the active mitochondria of
living cells: 50 nM, 20 min incubation, RT. The reduction of
ΔΨm was detected by flow cytometry as a decrease in red
fluorescence of the dye in treated cells as compared to
untreated cells.
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Conclusions
The anticancer activity and molecular mechanisms of action of
trans-platinum complexes have been extensively studied in the
last 20 years. Continuing our study on metal complexes of
3-aminoflavone, this study describes the synthesis, characteri-
zation and in vitro activity of trans-bis-(3-aminoflavone)dichlorido-
platinum(II) (trans-Pt(3-af)2Cl2; TCAP) in tumour models
(L1210, L1210R, HL-60, HeLa, EJ, EJcisR) and human lympho-
cytes in vitro. Spectroscopic studies indicate that the 3-amino-
flavone ligand is present in a chloride complex of trans-Pt(II).
Furthermore, X-ray diﬀraction studies have confirmed that the
central platinum(II) atom is four-coordinated by two nitrogen
atoms of 3-aminoflavone ligand and two chloride anions. The
compound is slightly less active than cisplatin against both
the tested cell lines and cisplatin-resistant cell lines. Despite
the fact that TCAP is slightly less active than cisplatin towards
cancer-resistant cells (L1210R and EJcisR), it possesses a much
lower resistance factor than cisplatin. Furthermore, trans-
Pt(3-af)2Cl2 was also less toxic for normal lymphocytes in com-
parison with cisplatin, which is a promising feature for a
potential anticancer agent, as it should be toxic to tumours
and safe for healthy tissues.
Even though TCAP has a lower cytotoxicity than cisplatin
after 72 hours of treatment, a higher percentage of apoptotic
cells is observed for TCAP than cisplatin in tested cell lines
after shorter periods of time. It may indicate that TCAP activity
has an earlier onset than cisplatin activity. This occurrence
may not be completely unexpected, in that the trans and cis-
conformation compounds are likely to diﬀer in their nature of
binding with DNA. Apoptotic cell death involves a series of
morphological and biochemical changes, including phos-
phatidylserine externalization and activation of caspase-3, and
suggests that this process is dependent upon events associated
with the loss of mitochondrial inner transmembrane potential
(ΔΨm). In addition, the TCAP molecule may be more lipophilic
than cisplatin (log P respectively 2.26 vs. −4.58), which may
enhance its transmembrane transport.42
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